- About the Center
- Patient Care
- Patient's Guide
- Professional's Guide
- Foreign Languages
- Faculty & Staff
- Mailing List
- Contact us
- PDCRC Blog
Selegilineis an inhibitor of the enzyme MAO-B (monoamine oxidase B). MAO-B breaks down dopamine. When it is inhibited, the action of dopamine is prolonged in the brain, and the symptoms of Parkinson's disease are improved. MAO-B inhibitors also have a mild antidepressant effect. Early studies of selegiline suggested that it may delay the progression of Parkinson's disease but this appears to have been confounded by a mild symptomatic effect. Currently there is no firm evidence that selegiline slows disease progression. It is effective as monotherapy for symptomatic relief or as an adjunctive agent.
Selegiline preparations include:
Side effects include heartburn, nausea, dry mouth, insomnia and dizziness. Confusion, nightmares, hallucinations, and headache occur less frequently.
Rasagiline is another MAO-B inhibitor that has been approved for monotherapy and adjunct therapy in Parkinson’s disease. It is taken once daily and is less likely to cause insomnia than selegiline. A recent study showed that treatment with 1 mg rasagiline provided benefits that were consistent with a possible disease-modifying (or neuroprotective) effect whereas treatment with 2 mg daily did not (Olanow et al, 2009)
Side effects include abnormal movements and hallucinations (when taken with levodopa), headache, and fatigue.
Precautions when using MAO-B inhibitors
Meperidine (Demerol®) and tramadol are contraindicated. Dextromethorphan and ephedrine should also be avoided, as should over-the-counter cold remedies. Treatment with ciprofloxacin may increase the blood level of rasagiline and so concomitant use should be avoided.